Switch to:
More From Other Websites
What’s Regeneron Expecting for Revenue in 1Q16? Apr 28 2016
Could Xtandi’s Use for Breast Cancer Be a Valuation Driver? Apr 18 2016
Biotech Regain Health: ETFs to Prescribe Apr 07 2016
Neurocrine Biosciences’ Valbenazine Launch: What You Need to Know Apr 06 2016
Q1 ETF Asset Report: Safe Havens Pop; Currency Hedged Drop Mar 31 2016
Focus 5 ETF Makes Another Change Mar 31 2016
Focus 5 ETF Gets A Dynamic Counterpart Mar 21 2016
BioMarin’s Naglazyme Sales Dipped by 31.3% Last Year Mar 07 2016
February ETF Asset Update: Safe Assets Gain; Stocks Shed Mar 02 2016
Is The Biotech Bear Market Over? Feb 29 2016
Understanding Regeneron’s Premium Valuation Feb 23 2016
Regeneron Pharmaceuticals’ Major Revenue Sources in 4Q15 Feb 12 2016
Transportation, Jets ETFs Speed Up As Oil Falls Below $28 Feb 09 2016
Biotech ETFs Slide as Stocks Report Mixed Q4 Results Feb 09 2016
Popular ETF Of ETFs Gets Defensive After Market Slide Feb 08 2016
The FV Shuffle: Giant ETF Trades? No Problem! Feb 08 2016
Big Dorsey Wright ETF Gets Defensive After Sharp Drop Feb 05 2016


No Entry for this criteria! We are updating our databases daily, please come back later!

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK